Arca
Skip to content
Tools
Tools

Hematological malignancies

Drug research and approvals for hematological malignancies: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 471 studies of hematological malignancies are recruiting on ClinicalTrials.gov, and Health Canada has authorized 33 drug trials for it since 2013.

  • Recruiting worldwide: 471
  • Trials authorized in Canada: 33
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 471 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,259 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 275 whose ending is known, 33% met their primary endpoint, 1% missed it and 65% stopped early.

  • Completed, result not reported42834%
  • Ongoing40732%
  • Status unknown14912%
  • Stopped: other or unclear947%
  • Met its primary endpoint927%
  • Stopped: enrollment or feasibility423%
  • Stopped: sponsor or business decision232%
  • Stopped: lack of efficacy151%
  • Missed its primary endpoint4<1%
  • Stopped: safety3<1%
  • Stopped: funding2<1%

Trials authorized in Canada

The 10 newest of 33; search them all in Canada trials
Nov 13, 2026Dualis: a modular phase I/II, open-label, multicentre study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and…AZD1221AstraZeneca PharmaceuticalsPending
Jul 15, 2026A phase 3, prospective, open-label, multicenter, single-arm study to investigate the efficacy, safety, and pharmacokinetics of IGPRO20 in subjects with…HizentraCSLPending
Aug 15, 2024Lightbeam-U01 substudy 01a: a phase 1/2 substudy to evaluate the safety and efficacy of zilovertamab vedotin in pediatric and young adult participants with…Zilovertamab vedotin (MK-2140) / Patritumab deruxtecan / Ifinatamab deruxtecanMerck & Co. (MSD)Ongoing
May 3, 2024Cold versus room temperature storage of platelets for bleeding in hematologic malignancy a pilot trial (coverts-hm)Apheresis platelets psoralen treated / Pooled platelets psoralen treatedOttawa Hospital Research InstitutePending
Aug 22, 2023An open-label, multicenter, roll-over study for patients who have completed a prior novartis-sponsored sabatolimab (MBG453) study and are judged by the…MBG453Novartis PharmaceuticalsOngoing
Apr 26, 2023A phase 1 open-label, multi-center, safety and efficacy study of PRT2527 as monotherapy and in combination with zanubrutinib or venetoclax in participants with…PRT2527 / Zanubrutinib/ VenetoclaxPrelude TherapeuticsClosed
Apr 13, 2023Phase 1/2 study of 9-ING-41, a glycogen synthase KINASE-3 beta (GSK-3B) inhibitor, as a single agent and combined with chemotherapy, in patients with…Elraglusib (9-ING-41)Actuate TherapeuticsOngoing
Aug 6, 2021A phase 2, open-label study to evaluate the safety and efficacy of mk- 7684a (MK-7684 [vibostolimab] with MK-3475 [pembrolizumab] coformulation) in…MK-7684A (vibostolimab + pembrolizumab)Merck & Co. (MSD)Ongoing
Jul 9, 2021Infusion of ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, for refractory/recurring infection or disease…ATIR101Hopital Maisonneuve RosemontPending
Feb 4, 2021A phase 2 study to evaluate the efficacy and safety of MK-1026 in participants with hematologic malignanciesNemtabrutinib (MK-1026)Merck & Co. (MSD)Ongoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.